NO20013414D0 - Ny anvendelse av melagatran - Google Patents

Ny anvendelse av melagatran

Info

Publication number
NO20013414D0
NO20013414D0 NO20013414A NO20013414A NO20013414D0 NO 20013414 D0 NO20013414 D0 NO 20013414D0 NO 20013414 A NO20013414 A NO 20013414A NO 20013414 A NO20013414 A NO 20013414A NO 20013414 D0 NO20013414 D0 NO 20013414D0
Authority
NO
Norway
Prior art keywords
melagatran
new use
prodrug
inflammation
medicament
Prior art date
Application number
NO20013414A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013414L (no
Inventor
Ian Kirk
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20013414L publication Critical patent/NO20013414L/no
Publication of NO20013414D0 publication Critical patent/NO20013414D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
NO20013414A 1999-01-13 2001-07-10 Ny anvendelse av melagatran NO20013414D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900070A SE9900070D0 (sv) 1999-01-13 1999-01-13 New use
PCT/SE2000/000051 WO2000041716A1 (en) 1999-01-13 2000-01-13 New use of melagatran

Publications (2)

Publication Number Publication Date
NO20013414L NO20013414L (no) 2001-07-10
NO20013414D0 true NO20013414D0 (no) 2001-07-10

Family

ID=20414074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013414A NO20013414D0 (no) 1999-01-13 2001-07-10 Ny anvendelse av melagatran

Country Status (20)

Country Link
US (3) US6683054B1 (pt)
EP (1) EP1150704B1 (pt)
JP (1) JP2002534477A (pt)
KR (1) KR100701539B1 (pt)
CN (1) CN1170592C (pt)
AT (1) ATE319473T1 (pt)
AU (1) AU767077B2 (pt)
BR (1) BR0007452A (pt)
CA (1) CA2356611A1 (pt)
CY (1) CY1107465T1 (pt)
DE (1) DE60026491T2 (pt)
DK (1) DK1150704T3 (pt)
ES (1) ES2257282T3 (pt)
IL (1) IL143985A0 (pt)
NO (1) NO20013414D0 (pt)
NZ (1) NZ512713A (pt)
PT (1) PT1150704E (pt)
SE (1) SE9900070D0 (pt)
WO (1) WO2000041716A1 (pt)
ZA (1) ZA200105275B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
DE10064797A1 (de) * 2000-12-22 2002-06-27 Knoll Ag Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon
SE0101762D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab New use
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
SE0103590D0 (sv) * 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
SE0203349D0 (sv) * 2002-11-12 2002-11-12 Astrazeneca Ab New use
WO2011126903A2 (en) 2010-03-30 2011-10-13 Verseon, Inc. Multisubstituted aromatic compounds as inhibitors of thrombin
NZ711064A (en) 2013-03-15 2019-06-28 Verseon Corp Pyridone-substituted pyrazolyl compounds as serine protease inhibitors
CN110423221A (zh) 2013-03-15 2019-11-08 维颂公司 作为凝血酶抑制剂的卤代吡唑
WO2016044662A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
HUE060104T2 (hu) 2015-02-27 2023-01-28 Verseon Int Corporation Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok
JP2021531338A (ja) 2018-07-13 2021-11-18 ヴァーセオン インターナショナル コーポレイション トロンビン阻害薬、製剤、及びそれらの使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9600216D0 (sv) * 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
US5669754A (en) * 1996-04-22 1997-09-23 Advanced Dynamics Corporation Ltd. Method and apparatus for collecting plates
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
JP2002525298A (ja) 1998-09-28 2002-08-13 メルク エンド カムパニー インコーポレーテッド トロンビン阻害剤の投与による炎症疾患の処置法
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.

Also Published As

Publication number Publication date
JP2002534477A (ja) 2002-10-15
ES2257282T3 (es) 2006-08-01
BR0007452A (pt) 2001-10-16
US6683054B1 (en) 2004-01-27
EP1150704A1 (en) 2001-11-07
WO2000041716A1 (en) 2000-07-20
AU2336100A (en) 2000-08-01
DE60026491D1 (de) 2006-05-04
CY1107465T1 (el) 2012-12-19
CA2356611A1 (en) 2000-07-20
IL143985A0 (en) 2002-04-21
ATE319473T1 (de) 2006-03-15
AU767077B2 (en) 2003-10-30
KR20010101492A (ko) 2001-11-14
KR100701539B1 (ko) 2007-03-30
NO20013414L (no) 2001-07-10
US20080058303A1 (en) 2008-03-06
US20040082518A1 (en) 2004-04-29
DK1150704T3 (da) 2006-06-12
EP1150704B1 (en) 2006-03-08
DE60026491T2 (de) 2006-11-02
NZ512713A (en) 2004-10-29
CN1341028A (zh) 2002-03-20
SE9900070D0 (sv) 1999-01-13
CN1170592C (zh) 2004-10-13
PT1150704E (pt) 2006-06-30
ZA200105275B (en) 2002-09-26

Similar Documents

Publication Publication Date Title
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
NO20031019D0 (no) Vedvarende frigivelsesformuleringer av oksymorfon
BG106586A (en) Pyrazolopyramidines as therapeutic agents
JO2282B1 (en) Oxazole derivatives
SE9900961D0 (sv) Novel compounds
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
SE0101932D0 (sv) Pharmaceutical combinations
SE9802208D0 (sv) Novel compounds
PL351710A1 (en) Anti−inflammatory therapy for inflammatory mediated infection
ATE360428T1 (de) Analgetisches arzneimittel
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
SE9802209D0 (sv) Novel compounds
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
AU2173101A (en) Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
SE0300535D0 (sv) Treatment of burns
ATE371446T1 (de) Zusammensetzungen zur verhinderung der adhäsion
SE0101762D0 (sv) New use
DE50112512D1 (de) Phenanthridinderivate und phenanthridin enthaltende antitumorale arzneimittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application